BTK Inhibitor Zanubrutinib Appears Promising in Waldenström Macroglobulinemia

BeiGene released results from its phase 1 clinical trial of the investigational BTK inhibitor zanubrutinib.

from Latest articles from Cancer Therapy Advisor News https://ift.tt/2PCnkCv